Establishment of Contextually Appropriate Cut Offs for Orthopoxvirus Serologic Assays in an Mpox-Endemic Setting

This study establishes context-specific serological cutoff values for three key orthopoxvirus antigens (E8L, A35R, and B6R) using a Mesoscale Discovery platform to effectively distinguish Mpox survivors from individuals with other orthopoxvirus exposures or vaccination histories in the Democratic Republic of the Congo.

The Gist

Imagine the Mpox virus (formerly known as Monkeypox) as a notorious shape-shifter that has been causing trouble around the world, leading to two major global health alarms in 2022 and 2024. While doctors are great at spotting the virus right now using a "swab test" (like a smoke detector that screams when it sees smoke), they need a different tool to find out who has been infected in the past or who had a silent infection that never showed symptoms. This is where blood tests come in—they act like a "history book" of your immune system, showing what the virus has fought before.

However, there's a problem. Most of these blood tests were designed in laboratories far away from where the virus actually lives naturally, like in the Democratic Republic of the Congo (DRC). It's like trying to use a map of New York City to navigate the jungles of the Congo; the landmarks don't match, and you might get lost. In the DRC, people have been exposed to many different "cousin" viruses (other Orthopoxviruses) and vaccines over the years. This makes it very hard to tell if a positive blood test means someone had Mpox recently, or if it's just a false alarm caused by an old exposure to a different, harmless cousin virus.

The Mission:
This study is like a team of detectives trying to create a customized "ID card" system specifically for the DRC. Their goal was to figure out the exact "score" needed on a blood test to say, "Yes, this person definitely had Mpox," versus "No, this is just a reaction to a different virus."

How They Did It:

1. The Suspects: They gathered blood samples from 134 people, splitting them into six different groups based on their history (some had Mpox, some had other viruses, some had vaccines, and some had nothing).
2. The Test: They used a high-tech scanner (called MSD) to check for five specific "wanted posters" (antigens) that the virus leaves behind. Think of these antigens as unique fingerprints left at the crime scene.
3. The Filter: They used a mathematical tool (called ROC analysis) to act as a sieve, filtering out the noise to find which fingerprints were the most reliable for catching the real culprit.

The Big Discovery:
The researchers found that while they looked at five different fingerprints, only three were the "superstars" for telling the difference between a Mpox survivor and someone who just met a virus cousin. These three are named E8L, A35R, and B6R.

• The Analogy: Imagine you are trying to identify a specific type of thief in a crowd. You might look at their hat, shoes, and coat. You might find that the hat and shoes are common to many people, but the coat is unique to the thief. In this study, the "coat" is the combination of those three specific antigens.
• The Result: By setting a specific "score" (a cutoff) for these three antigens, the team created a binary rule (a simple Yes/No switch). If a person's blood score hits these specific numbers, the test can confidently say, "This person survived Mpox," separating them clearly from everyone else in the crowd.

Why It Matters:
This study provides a custom-made key for the DRC. Instead of using a generic key that doesn't fit the local locks, health officials now have a precise tool to accurately track who has had Mpox, understand how the virus spreads in that specific region, and make better decisions for future outbreaks. It turns a blurry, confusing picture into a clear, sharp image.

Technical Summary

Technical Summary: Establishment of Contextually Appropriate Cut Offs for Orthopoxvirus Serologic Assays in an Mpox-Endemic Setting

1. Problem Statement

The rapid global spread of the Mpox virus (MPXV), highlighted by two Public Health Emergencies of International Concern (PHEICs) in 2022 and 2024, has underscored the limitations of current diagnostic frameworks. While Polymerase Chain Reaction (PCR) remains the gold standard for detecting active infections, it cannot identify past or asymptomatic cases, which are critical for understanding transmission dynamics and historical exposure.

A significant gap exists in serological surveillance: many assays developed during recent outbreaks have not been validated in endemic settings like the Democratic Republic of the Congo (DRC). In these regions, populations often have complex exposure histories involving multiple Orthopoxviruses (OPXV) and varying vaccination statuses (e.g., smallpox vaccination). Consequently, existing serological cutoffs often fail to distinguish between MPXV-specific seroconversion and cross-reactivity from other OPXV exposures or prior vaccinations, leading to potential misclassification in surveillance data.

2. Methodology

To address these challenges, the study employed a rigorous, antigen-specific approach to define contextually appropriate serological cutoffs for the DRC.

• Cohort Design: The study analyzed serum samples from 134 individuals, stratified into six distinct cohorts based on their specific exposure histories (e.g., MPXV survivors, individuals with other OPXV exposure, and various vaccination histories).
• Assay Platform: Samples were screened using Mesoscale Discovery (MSD) technology, a high-sensitivity electrochemiluminescence platform.
• Antigen Panel: The screening targeted five pairs of orthologous antigens shared between MPXV and Vaccinia Virus (VACV):
  • A29L / A27L
  • A35R / A33R
  • B6R / B5R
  • E8L / D8L
  • M1R / L1R
• Statistical Analysis:
  • Receiver Operating Characteristic (ROC) Analysis: Used to evaluate the discriminatory power of each antigen and determine the optimal cutoff values that maximize sensitivity and specificity.
  • Binary Composite Rule: A multi-antigen algorithm was evaluated to improve classification accuracy beyond single-antigen thresholds.

3. Key Contributions

• Context-Specific Validation: This study provides the first robust validation of MPXV serological assays specifically tailored for an endemic setting (DRC), addressing the critical lack of data from regions with high OPXV diversity.
• Antigen-Specific Cutoffs: The research moves beyond generic cutoffs by establishing precise, quantitative thresholds (in AU/mL) for specific antigens that differentiate MPXV infection from background OPXV noise.
• Optimized Panel Identification: The study identifies a specific subset of antigens that, when combined, offer superior diagnostic performance compared to individual markers or broader, less specific panels.

4. Key Results

The analysis yielded three high-performing MPXV antigens that demonstrated the strongest ability to discriminate between MPXV survivors and other OPXV-exposed individuals:

1. E8L: Established cutoff of 12.33 AU/mL.
2. A35R: Established cutoff of 5.22 AU/mL.
3. B6R: Established cutoff of 9.77 AU/mL.

Performance Outcome:

• These three antigens collectively formed a significant serological panel.
• The application of this panel resulted in a clear separation between the MPXV survivor cohort and individuals with exposure to other Orthopoxviruses or different vaccination histories.
• The binary composite rule utilizing these antigens significantly reduced false positives associated with cross-reactivity, enhancing the reliability of retrospective surveillance.

5. Significance

The establishment of these contextually appropriate cutoffs is pivotal for public health strategy in endemic regions:

• Improved Surveillance: Enables accurate mapping of historical MPXV transmission and the identification of asymptomatic cases, which are crucial for modeling outbreak dynamics.
• Vaccine Evaluation: Provides a reliable tool to assess the immunogenicity and efficacy of MPXV vaccines in diverse populations with prior OPXV exposure.
• Diagnostic Precision: Reduces the risk of misdiagnosis in regions where smallpox vaccination or exposure to other animal poxviruses is common, ensuring that serological data accurately reflects true MPXV burden.
• Global Readiness: Offers a validated framework that can be adapted for other endemic regions, strengthening global preparedness for future Orthopoxvirus outbreaks.